5 Key Takeaways

• 1

  Sulthiame has shown dose-dependent reductions in apneic episodes in patients with obstructive sleep apnea, according to a recent study.

• 2

  The randomized trial involved 298 patients who received either sulthiame or a placebo, with assessments at baseline, 4 weeks, and 12 weeks.

• 3

  Patients in the 300 mg sulthiame group experienced a 39.9% reduction in the apnea-hypopnea index at week 12.

• 4

  Sulthiame improved overnight oxygen saturation and reduced daytime sleepiness, with mild to moderate side effects reported.

• 5

  Further phase III trials are planned to confirm sulthiame's long-term safety and efficacy for obstructive sleep apnea.